Decrease in levels of Fas ligand with treatment (Rx) in 14 patients with large granulocyte lymphocyte leukemia
| Patient . | Indication for Rx . | Rx . | Clinical Response . | Molecular Response . | Fas Ligand Before Rx (mmol/L) . | Fas Ligand During Rx (mmol/L) . |
|---|---|---|---|---|---|---|
| 1 | Neutropenia | MTX | CR | Yes | 0.56 | Undetectable |
| 2 | Neutropenia | MTX | CR | No | 0.28 | Undetectable |
| 3 | Neutropenia | MTX | CR | Yes | 0.21 | Undetectable |
| 4 | Neutropenia | MTX | CR | No | 0.57 | 0.12 |
| 5 | Neutropenia | MTX | CR | Yes | 0.32 | Undetectable |
| 6 | Neutropenia | MTX | PR | — | 0.64 | 0.27 |
| 7 | Neutropenia | MTX | PR | — | 0.54 | Undetectable |
| 8 | Neutropenia | MTX | CR | ND | 2.18 | 0.81 |
| 9 | Neutropenia | MTX | CR | No | 1.38 | Undetectable |
| 10 | Neutropenia | 2CdA | CR | Yes | 0.39 | 0.11 |
| 11 | Neutropenia | MTX | CR | Yes | 0.31 | 0.29 |
| 12 | Neutropenia | None | CR | No | 1.24 | Undetectable |
| 13 | Anemia | MTX | CR | ND | 0.81 | Undetectable |
| 14 | Anemia | Cy | PR | — | 0.47 | 0.13 |
| Patient . | Indication for Rx . | Rx . | Clinical Response . | Molecular Response . | Fas Ligand Before Rx (mmol/L) . | Fas Ligand During Rx (mmol/L) . |
|---|---|---|---|---|---|---|
| 1 | Neutropenia | MTX | CR | Yes | 0.56 | Undetectable |
| 2 | Neutropenia | MTX | CR | No | 0.28 | Undetectable |
| 3 | Neutropenia | MTX | CR | Yes | 0.21 | Undetectable |
| 4 | Neutropenia | MTX | CR | No | 0.57 | 0.12 |
| 5 | Neutropenia | MTX | CR | Yes | 0.32 | Undetectable |
| 6 | Neutropenia | MTX | PR | — | 0.64 | 0.27 |
| 7 | Neutropenia | MTX | PR | — | 0.54 | Undetectable |
| 8 | Neutropenia | MTX | CR | ND | 2.18 | 0.81 |
| 9 | Neutropenia | MTX | CR | No | 1.38 | Undetectable |
| 10 | Neutropenia | 2CdA | CR | Yes | 0.39 | 0.11 |
| 11 | Neutropenia | MTX | CR | Yes | 0.31 | 0.29 |
| 12 | Neutropenia | None | CR | No | 1.24 | Undetectable |
| 13 | Anemia | MTX | CR | ND | 0.81 | Undetectable |
| 14 | Anemia | Cy | PR | — | 0.47 | 0.13 |
MTX indicates oral low-dose methotrexate; CR, complete response; PR, partial response; ND, evaluation not done; 2CdA, 2-chlorodeoxyadenosine; and Cy, oral low-dose cyclophosphamide. A dash indicates not applicable, as patient did not achieve CR.